Overview

Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion

Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to compare breast symptoms (lactation, engorgement, etc) of individuals who undergo a procedure for second trimester of pregnancy loss between 16 weeks and 20 weeks gestational age. The participants will be randomly placed in two groups, one with a placebo tablet and one with medication called "cabergoline" which are taken immediately after their procedure. Researchers will compare groups to see if there are any significant differences in breast symptoms.
Phase:
Phase 4
Details
Lead Sponsor:
Northwestern University
Treatments:
Cabergoline